Transdermal contraceptive patches: current status and future potential

References

• Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 national survey of family growth. Contraception77(1), 10–21 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J. Reprod. Med.40(5), 355–360 (1995).
   PubMed Web of Science ®Google Scholar
• Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation. Obstet. Gynecol.112(4), 782–787 (2008).
   PubMed Web of Science ®Google Scholar
• Foster DG, Parvataneni R, de Bocanegra HT, Lewis C, Bradsberry M, Darney P. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet. Gynecol.108(5), 1107–1114 (2006).
   PubMed Web of Science ®Google Scholar
• Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam. Plann. Perspect.28(4), 154–158 (1996).
   PubMedGoogle Scholar
• Burkman RT. Transdermal hormonal contraception: benefits and risks. Am. J. Obstet. Gynecol.197(2), 134.e1–134.e6 (2007).
   PubMed Web of Science ®Google Scholar
• Creasy GW, Abrams LS, Fisher AC. Transdermal contraception. Semin. Reprod. Med.19(4), 373–380 (2001).
   PubMedGoogle Scholar
• Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am. J. Obstet. Gynecol.151(7), 868–877 (1985).
   PubMed Web of Science ®Google Scholar
• Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil. Steril.77(2 Suppl. 2), S3–S12 (2002).
   PubMed Web of Science ®Google Scholar
• Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC; Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose–response study. Am. J. Obstet. Gynecol.186(1), 15–20 (2002).
   Web of Science ®Google Scholar
• Abrams LS, Skee DM, Natarajan J, Wong FA, Anderson GD. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br. J. Clin. Pharmacol.53(2), 141–146 (2002).
   PubMed Web of Science ®Google Scholar
• Murthy AS, Creinin MD, Harwood B, Schreiber CA. Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception72(5), 333–336 (2005).
   Google Scholar
• Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet. Gynecol.105(6), 1389–1396 (2005).
   PubMed Web of Science ®Google Scholar
• LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil. Steril.83(6), 1875–1877 (2005).
   PubMedGoogle Scholar
• Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil. Steril.80(1), 34–42 (2003).
   PubMed Web of Science ®Google Scholar
• Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress. Prescrire Int.13(72), 123–126 (2004).
   Google Scholar
• Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil. Steril.77(2 Suppl. 2), S32–S35 (2004).
   Google Scholar
• Abrams LS, Skee DM, Natarajan J et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J. Clin. Pharmacol.41(12), 1301–1309 (2001).
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril.77(2 Suppl. 2), S13–S18 (2002).
   PubMed Web of Science ®Google Scholar
• Audet MC, Moreau M, Koltun WD et al.; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA285(18), 2347–2354 (2001).
   PubMed Web of Science ®Google Scholar
• Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception69(3), 189–195 (2004).
   PubMed Web of Science ®Google Scholar
• Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst. Rev. (1), CD003552 (2003).
   Google Scholar
• Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J. Adolesc. Health34(5), 395–401 (2004).
   Google Scholar
• Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. ScientificWorldJournal4, 512–516 (2004).
   PubMedGoogle Scholar
• Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents’ experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J. Pediatr. Adolesc. Gynecol.18(2), 85–90 (2005).
   PubMedGoogle Scholar
• Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J. Pediatr. Adolesc. Gynecol.20(2), 61–65 (2007).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical Eligibility Criteria for Contraceptive Use: 2008 update. World Health Organization, Geneva, Swtizerland, 2008.
   Google Scholar
• Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil. Steril.77(2 Suppl. 2), S19–S26 (2002).
   PubMed Web of Science ®Google Scholar
• Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW; ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet. Gynecol.98(5 Pt 1), 799–805 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada, 22–25 March 2006.
   Google Scholar
• Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet. Gynecol.109(2 Pt 1), 339–346 (2007). Erratum in: Obstet. Gynecol.111(6), 1449 (2008).
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception73(3), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception76(1), 4–7 (2007).
   PubMed Web of Science ®Google Scholar
• Boston Collaborative Drug Surveillance Program. Postmarketing Study of ORTHO EVRA® and Levonorgestrel Oral Contraceptives in Relation to Non-Fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction. 1 April 2002–31 March 2006.
   Google Scholar
• Creinin MD, Meyn LA, Borgatta L et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet. Gynecol.111(2 Pt 1), 267–277 (2008).
   PubMed Web of Science ®Google Scholar
• Gracia CR, Sammel MD, Charlesworth S, Lin H, Barnhart KT, Creinin MD. Sexual function in first-time contraceptive ring and contraceptive patch users. Fertil. Steril. doi:10.1016/j.fertnstert.2008.09.066 (2008) (Epub ahead of print).
   Google Scholar
• Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). J. Fam. Plann. Reprod. Health Care30(1), 43–45 (2004).
   Google Scholar
• Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur. J. Contracept. Reprod. Health Care9(3), 173–181 (2004).
   PubMed Web of Science ®Google Scholar